Marina Ciomei

Milan, 20014, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

Journal: ACS medicinal chemistry letters

Published: November 22, 2018

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Journal: Molecular cancer therapeutics

Published: September 11, 2015

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: July 30, 2015

Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.

Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.

Journal: Bioorganic & medicinal chemistry

Published: January 12, 2015

Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.

Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.

Journal: ChemMedChem

Published: September 30, 2014

Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.

Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: May 06, 2014

NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.

NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 16, 2013

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.

Journal: Biochemical pharmacology

Published: April 12, 2012

Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.

Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.

Journal: British journal of pharmacology

Published: March 27, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026